The discovery of penicillin led to the development of natural, semi-synthetic, and synthetic antimicrobial medications. Quickly thereafter, resistant strains of microorganisms began appearing around the globe. Methicillin-resistant S. aureus, especially community-acquired MRSA, is increasingly a problem in pregnant women and in the postpartum period. The rate of MRSA infections in pregnant women, between 2000 and 2004, increased 10-fold. Postparturritional infections due to the MRSA are often serious and potentially life- threatening. Vancomycin has been the antibiotic of choice for treatment of infections caused by MRSA;however, the development of vancomycin-resistant strains of Staphylococcus aureus (VRSA) compromised its use and led to the development of its derivative telavancin. However, neither medication is approved for treatment of these infections in the pregnant patient. The hypoithesis for the proposed work is that changes in maternal physiology during pregnancy and the development of the feto-placental compartment will affect drug disposition and, consequently, pharmacokinetics (PK) and pharmacodynamics (PD) of vancomycin and telavancin. Therefore, the goal of the clinical pharmacology and translational projects proposed is to provide fundamental and necessary information that is elemental in making these 2 medications available for treatment of MRSA and VRSA infections during pregnancy. To achieve this goal, the following specific aims will be investigated: For the clinical trial-(1) The PK of vancomycin and telavancin, (2) Perinatal and maternal outcome, and (3) Neonatal outcome. For the translational project-(1) Determine the ex vivo placental transfer of the 2 antibiotics, (2) Identify the enzymes responsible for their biotransformation and the metabolites formed, (3) Determine the role and activity of placental uptake and efflux transporters and their effect on the extent of fetal exposure to the 2 antibiotics, and (4) Determine the effect of polymorphisms in the genes expressing the responsible metabolizing enzymes and transporters on their activity. The data obtained will provide the most basic information required for determination of the dose of each medication administered during pregnancy;its effect on perinatal, maternal, and neonatal outcomes;the extent to which the placenta regulates its transfer to the fetal circulation;and whether it is affected by genetic variables that could be liked to ethnicity of either the mother, fetus, or both.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10HD047891-10
Application #
8600296
Study Section
Special Emphasis Panel (ZHD1-DSR-Z (02))
Program Officer
Ren, Zhaoxia
Project Start
2004-07-01
Project End
2014-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
10
Fiscal Year
2014
Total Cost
$940,892
Indirect Cost
$320,745
Name
University of Texas Medical Br Galveston
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Zhang, Xing; Vernikovskaya, Daria I; Wang, Xiaoming et al. (2016) Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS. Biomed Chromatogr 30:548-54
Costantine, Maged M; Cleary, Kirsten; Hebert, Mary F et al. (2016) Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 214:720.e1-720.e17
Fokina, Valentina M; Xu, Meixiang; Rytting, Erik et al. (2016) Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy. Drug Metab Dispos 44:1832-1838
Ryu, Rachel J; Eyal, Sara; Easterling, Thomas R et al. (2016) Pharmacokinetics of metoprolol during pregnancy and lactation. J Clin Pharmacol 56:581-9
Pillai, Venkateswaran C; Han, Kelong; Beigi, Richard H et al. (2015) Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. Br J Clin Pharmacol 80:1042-50
Zhang, Xing; Wang, Xiaoming; Vernikovskaya, Daria I et al. (2015) Quantitative determination of metformin, glyburide and its metabolites in plasma and urine of pregnant patients by LC-MS/MS. Biomed Chromatogr 29:560-9
Ryu, Rachel J; Eyal, Sara; Kaplan, Henry G et al. (2014) Pharmacokinetics of doxorubicin in pregnant women. Cancer Chemother Pharmacol 73:789-97
Wang, Xiaoming; Paul, Jonathan A; Nanovskaya, Tatiana N et al. (2014) Quantitative determination of telavancin in pregnant baboon plasma by solid-phase extraction and LC-ESI-MS. J Pharm Biomed Anal 98:107-12
Beigi, Richard H; Venkataramanan, Raman; Caritis, Steve N (2014) Oseltamivir for influenza in pregnancy. Semin Perinatol 38:503-7
Rytting, Erik; Nanovskaya, Tatiana N; Wang, Xiaoming et al. (2014) Pharmacokinetics of indomethacin in pregnancy. Clin Pharmacokinet 53:545-51

Showing the most recent 10 out of 37 publications